Safety of Bevacizumab in elderly Moroccan patients with metastatic colorectal cancer

Rachid Tanz; Tarik Mahfoud; Aziz Bazine; Ilyas El Alami; Mohamed Reda Khmamouch; Choukri El Mhadi; Mehdi Toreis; Hassan Errihani; Mohamed Ichou

Volume : VII, Issue : III, March - 2018

Safety of Bevacizumab in elderly Moroccan patients with metastatic colorectal cancer

Rachid Tanz, Tarik Mahfoud, Aziz Bazine, Ilyas El Alami, Mohamed Reda Khmamouch, Choukri El Mhadi, Mehdi Toreis, Hassan Errihani, Mohamed Ichou

Abstract :

Background

Colorectal cancer is the most frequent digestive cancer. The incidence and mortality of CRC increases in elderly patients. Bevacizumab improves survival of mCRC patients at the price of particular toxicity profile that can be increased in an elderly population generally having comorbidities. The aim of this study was to evaluate the safety of use of Bevacizumab in elderly Moroccan patients with mCRC in real life.

Material and methods:

This was a retrospective observational study conducted in medical oncology unit of military hospital Mohamed V of Rabat. The study was conducted in a general patient population, including elderly patients, with mCRC who had been treated on first line Bevacizumab based chemotherapy between December 2009 and May 2014.

The primary objective was to assess the safety profile of Bevacizumab in elderly patients in combination with chemotherapy as first–line treatment of mCRC.

We analyses the safety of Bevacizumab for patients older than 65 years, which is a widely accepted age cutoff point for the definition of elderly.

Results

forty–seven patients were included in this study. The most frequent observed adverse event was hypertension in 19% of our patients followed by Proteinuria(14%), Thrombotic diseases (10%) ,Serious bleeding events (2%) and Fistulae (2%). There was no case of Ischemic heart disease or Perforations in our serie.

Conclusions

Despite the low statistical power of our study, the use of Bevacizumab in older Moroccan patients does not seem to ing an excess of toxicity compared with published reports. These results must be confirmed in most important studies.